Showing 6891-6900 of 9760 results for "".
- It's Eczema Awareness Monthhttps://practicaldermatology.com/news/its-eczema-awareness-month/2460932/Recognizing that the daily impact and overall burden of eczema for each individual can differ greatly from person to person and within a person's lifetime, the
- Bimekizumab Performs Well in Psoriasis with Results Lasting through Two Yearshttps://practicaldermatology.com/news/bimekizumab-performs-well-in-psoriasis-with-results-lasting-through-two-years/2460929/Interim results from the BE BRIGHT open-label extension (OLE) study showed clinical responses observed in bimekizumab-treated psoriasis patients during the first 16 weeks of BE SURE were sustained through to two years of treatment with continuous maintenance dosing, UCB reports. T
- FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreenshttps://practicaldermatology.com/news/fda-takes-steps-aimed-at-improving-quality-safety-and-efficacy-of-sunscreens/2460926/The U.S. Food and Drug Administration today took steps aimed at improving the quality, safety, and efficacy of sunscreens as part of its implementation of new authorities for certain over-the-counter (OTC) drugs. In the short term, these new authorities essentially preserve status
- Dermavant: First Patient Dosed in Phase 3 Study of Tapinarof in ADhttps://practicaldermatology.com/news/dermavant-first-patient-dosed-in-phase-3-study-of-tapinarof-in-ad/2460925/The first patient has been dosed in the Phase 3, double-blind, vehicle-controlled pivotal study of tapinarof for the treatment of atopic dermatitis (AD). Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development by
- Incyte's Opzelura is First Topical JAK Inhibitor Approved in UShttps://practicaldermatology.com/news/incyts-opzelura-is-first-topical-jak-inhibitor-approved-in-us/2460919/Opzelura™ (ruxolitinib) cream from Incyte is now the first and only topical formulation of a JAK inhibitor approved in the United States. FDA approved Opzelura for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis
- Accure Acne, Inc. Appoints Jeffrey O'Donnell, Sr. to the Boardhttps://practicaldermatology.com/news/accure-acne-inc-announces-the-appointment-of-jeffrey-odonnell-sr-to-the-board/2460918/Jeffrey O'Donnell, Sr. has joined Accure Acne's Board of Directors. Along with Chairman and Founder Christopher Carlton and Founder Ed Barbera, Mr. O'Donnell provides strategic guidance for Accure's i
- Dr. Eugene A. Bauer Joins American Skin Association Boardhttps://practicaldermatology.com/news/dr-eugene-a-bauer-joins-american-skin-association-board/2460915/Eugene Bauer, MD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Bauer is Professor, Emeritus, at Stanford University School of Medicine. He is immediate past co-founder, Chief Medical Officer, and member of the Board of Directors of Dermir
- New Global Initiative Aims to Improve Eczema Carehttps://practicaldermatology.com/news/new-global-initiative-aims-to-improve-eczema-care/2460913/The new Global Patient Initiative to Improve Eczema Care (GPIIEC) is a global collaboration to establish a common "yardstick" to assess the responsiveness of health systems to the needs of patients with eczema and their caregivers. The global
- World Atopic Eczema Day Focuses on Disease Awarenesshttps://practicaldermatology.com/news/world-atopic-eczema-day-focuses-on-disease-awareness/2460912/As patient communities worldwide join forces to raise awareness about atopic eczema, the International Alliance of Dermatology Patient Organisations (GlobalSkin) and the global atopic eczema community call on healthcare professionals, health policy decision ma
- Dermala Scores New Patent Covering the Use of Human Microbiome to Prevent, Slow, and Reverse Skin Aginghttps://practicaldermatology.com/news/dermala-scores-new-patent-covering-the-use-of-human-microbiome-to-prevent-slow-and-reverse-skin-aging/2460910/Dermala has received issuance of a U.S. Patent to use the human microbiome to slow down the skin aging process. The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adult